We believe that when IO-nanocages are used to deliver mGluR5 siRNAs to the targeted tumor site, AMFs application will enhance the release of mGluR5 siRNAs into the tumor site, which would result in tumor size shrinkage. This evidence concerns the gene GRM5 and neoplasm.